IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration

Science Translational Medicine

Volumn 6, Issue 230, 2014, Pages

  Doyle, Sarah L ^a,b   Ozaki, Ema ^c   Brennan, Kiva ^c   Humphries, Marian M ^c   Mulfaul, Kelly ^a,b   Keaney, James ^c   Kenna, Paul F ^c,d   Maminishkis, Arvydas ^e   Kiang, Anna Sophia ^c   Saunders, Sean P ^a   Hams, Emily ^a   Lavelle, Ed C ^c   Gardiner, Clair ^c   Fallon, Padraic G ^a   Adamson, Peter ^f   Humphries, Peter ^c   Campbell, Matthew ^c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^e NATIONAL EYE INSTITUTE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DMS 1529; RECOMBINANT INTERLEUKIN 18; SB 528775; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL SWELLING; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; AUTOPHAGY; CELL LINE; CELL SURVIVAL; CHOROIDAL NEOVASCULARIZATION; HEMATOPOIESIS; HUMANS; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTRAVITREAL INJECTIONS; LASERS; MACULAR DEGENERATION; MICE; MODELS, BIOLOGICAL; PERMEABILITY; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899078505     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007616     Document Type: Article

References (28)

1. D. B. Rein, J. S. Wittenborn, X. Zhang, A. A. Honeycutt, S. B. Lesesne, J. Saaddine; Vision Health Cost-Effectiveness Study Group, Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments. Arch. Ophthalmol. 127, 533-540 (2009).
2. C. A. Janeway, R. Medzhitov, Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
3. L. A. O'Neill, A. G. Bowie, The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353-364 (2007).
4. K. Schroder, J. Tschopp, The inflammasomes. Cell 140, 821-832 (2010).
5. R. D. Jager, W. F. Mieler, J. W. Miller, Age-related macular degeneration. N. Engl. J. Med. 358, 2606-2617 (2008).
6. CATT Research Group; D. F. Martin, M. G. Maguire, G. S. Ying, J. E. Grunwald, S. L. Fine, G. J. Jaffe, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897-1908 (2011).
7. J. S. Heier, D. M. Brown, V. Chong, J. F. Korobelnik, P. K. Kaiser, Q. D. Nguyen, B. Kirchhof, A. Ho, Y. Ogura, G. D. Yancopoulos, N. Stahl, R. Vitti, A. J. Berliner, Y. Soo, M. Anderesi, G. Groetzbach, B. Sommerauer, R. Sandbrink, C. Simader, U. Schmidt-Erfurth; VIEW 1 and VIEW 2 Study Groups, Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119, 2537-2548 (2012).
8. K. Kinnunen, G. Petrovski, M. C. Moe, A. Berta, K. Kaarniranta, Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol. 90, 299-309 (2012).
9. S. L. Doyle, M. Campbell, E. Ozaki, R. G. Salomon, A. Mori, P. F. Kenna, G. J. Farrar, A. S. Kiang, M. M. Humphries, E. C. Lavelle, L. A. O'Neill, J. G. Hollyfield, P. Humphries, NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 18, 791-798 (2012).
10. V. Tarallo, Y. Hirano, B. D. Gelfand, S. Dridi, N. Kerur, Y. Kim, W. G. Cho, H. Kaneko, B. J. Fowler, S. Bogdanovich, R. J. Albuquerque, W. W. Hauswirth, V. A. Chiodo, J. F. Kugel, J. A. Goodrich, S. L. Ponicsan, G. Chaudhuri, M. P. Murphy, J. L. Dunaief, B. K. Ambati, Y. Ogura, J. W. Yoo, D. K. Lee, P. Provost, D. R. Hinton, G. Núñez, J. Z. Baffi, M. E. Kleinman, J. Ambati, DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149, 847-859 (2012).
11. A. Kauppinen, H. Niskanen, T. Suuronen, K. Kinnunen, A. Salminen, K. Kaarniranta, Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells - Implications for age-related macular degeneration (AMD). Immunol. Lett. 147, 29-33 (2012).
12. W. A. Tseng, T. Thein, K. Kinnunen, K. Lashkari, M. S. Gregory, P. A. D'Amore, B. R. Ksander, NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: Implications for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 54, 110-120 (2013).
13. A. A. Tarhini, M. Millward, P. Mainwaring, R. Kefford, T. Logan, A. Pavlick, S. J. Kathman, K. H. Laubscher, M. M. Dar, J. M. Kirkwood, A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859-868 (2009).
14. M. J. Robertson, J. M. Kirkwood, T. F. Logan, K. M. Koch, S. Kathman, L. C. Kirby, W. N. Bell, L. M. Thurmond, J. Weisenbach, M. M. Dar, A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin. Cancer Res. 14, 3462-3469 (2008).
15. M. J. Robertson, J. W. Mier, T. Logan, M. Atkins, H. Koon, K. M. Koch, S. Kathman, L. N. Pandite, C. Oei, L. C. Kirby, R. C. Jewell, W. N. Bell, L. M. Thurmond, J. Weisenbach, S. Roberts, M. M. Dar, Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12, 4265-4273 (2006).
16. J. Golab, T. Stoklosa, Technology evaluation: SB-485232, GlaxoSmithKline. Curr. Opin. Mol. Ther. 7, 85-93 (2005).
17. N. V. Strunnikova, A. Maminishkis, J. J. Barb, F. Wang, C. Zhi, Y. Sergeev, W. Chen, A. O. Edwards, D. Stambolian, G. Abecasis, A. Swaroop, P. J. Munson, S. S. Miller, Transcriptome analysis and molecular signature of human retinal pigment epithelium. Hum. Mol. Genet. 19, 2468-2486 (2010).
18. S. J. Robbie, P. Lundh von Leithner, M. Ju, C. A. Lange, A. G. King, P. Adamson, D. Lee, C. Sychterz, P. Coffey, Y. S. Ng, J. W. Bainbridge, D. T. Shima, Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. Invest. Ophthalmol. Vis. Sci. 54, 1490-1500 (2013).
19. J. R. Sparrow, M. Boulton, RPE lipofuscin and its role in retinal pathobiology. Exp. Eye Res. 80, 595-606 (2005).
20. V. Compan, A. Baroja-Mazo, G. López-Castejón, A. I. Gomez, C. M. Martínez, D. Angosto, M. T. Montero, A. S. Herranz, E. Bazán, D. Reimers, V. Mulero, P. Pelegrín, Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 37, 487-500 (2012).
21. J. Viiri, M. Amadio, N. Marchesi, J. M. Hyttinen, N. Kivinen, R. Sironen, K. Rilla, S. Akhtar, A. Provenzani, V. G. D'Agostino, S. Govoni, A. Pascale, H. Agostini, G. Petrovski, A. Salminen, K. Kaarniranta, Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells. PLOS One 8, 1-16 (2013).
22. K. Kaarniranta, D. Sinha, J. Blasiak, A. Kauppinen, Z. Veréb, A. Salminen, M. E. Boulton, G. Petrovski, Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration. Autophagy 9, 973-984 (2013).
23. A. L. Wang, T. J. Lukas, M. Yuan, N. Du, M. O. Tso, A. H. Neufeld, Autophagy and exosomes in the aged retinal pigment epithelium: Possible relevance to drusen formation and age-related macular degeneration. PLOS One 4, e4160 (2009).
24. T. U. Krohne, N. K. Stratmann, J. Kopitz, F. G. Holz, Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp. Eye Res. 90, 465-471 (2010).
25. J. Harris, M. Hartman, C. Roche, S. G. Zeng, A. O'Shea, F. A. Sharp, E. M. Lambe, E. M. Creagh, D. T. Golenbock, J. Tschopp, H. Kornfeld, K. A. Fitzgerald, E. C. Lavelle, Autophagy controls IL-1β secretion by targeting pro-IL-1β for degradation. J. Biol. Chem. 286, 9587-9597 (2011).
26. A. A. Moshfeghi, P. J. Rosenfeld, C. A. Puliafito, S. Michels, E. N. Marcus, J. D. Lenchus, A. S. Venkatraman, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113, 2002.e1-2002.e12 (2006).
27. H. E. Grossniklaus, S. J. Kang, L. Berglin, Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 29, 500-519 (2010).
28. F. G. Bauernfeind, G. Horvath, A. Stutz, E. S. Alnemri, K. MacDonald, D. Speert, T. Fernandes-Alnemri, J. Wu, B. G. Monks, K. A. Fitzgerald, V. Hornung, E. Latz, Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009).